<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04718909</url>
  </required_header>
  <id_info>
    <org_study_id>MIIR-05</org_study_id>
    <nct_id>NCT04718909</nct_id>
  </id_info>
  <brief_title>Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC</brief_title>
  <acronym>REGSIN</acronym>
  <official_title>Regorafenib Combined With Sintilimab Versus Regorafenib Alone as the Second-line Treatment for Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZhuHai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Zhaoqing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fifth Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangmen Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Shenzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jieyang People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shantou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yuebei People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhaoqing Gaoyao People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital of Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to evaluate the efficacy and safety of regorafenib plus sintilimab&#xD;
      compared with regorafenib alone as the second-line treatment for patients with unresectable&#xD;
      hepatocellullar carcinoma (HCC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multicenter, randomized controlled trial to evaluate the efficacy and&#xD;
      safety of regorafenib plus sintilimab compared with regorafenib alone as the second-line&#xD;
      treatment for unresectable HCC.&#xD;
&#xD;
      180 patients with unresectable HCC who progress after sorafenib or lenvatinib treatment or&#xD;
      are intolerant to these drugs will be enrolled in the study. The Patients will be treated&#xD;
      with regorafenib plus sintilimab or regorafenib alone using an 1:1 randomization scheme.&#xD;
&#xD;
      Regorafenib will last until disease progresses, intolerable toxicity, withdrawal of informed&#xD;
      consent, loss of follow-up, death, or other circumstances that require termination of&#xD;
      treatment, whichever occurs first. The administration of regorafenib will be delayed in cases&#xD;
      of severe toxicities. And after recovery, regorafenib will be reintroduced at a reduced dose&#xD;
      according to the dose delay and reduction guidelines. Treatment of sintilimab will last up to&#xD;
      24 months, or until disease progresses, intolerable toxicity, withdrawal of informed consent,&#xD;
      loss of follow-up, death, or other circumstances that require termination of treatment,&#xD;
      whichever occurs first. In the arm of regorafenib plus sintilimab, patients will be allowed&#xD;
      to have regorafenib or sintilimab as a sigle agent and will be still considered on study when&#xD;
      the other drug cause intolerable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS) assessed by investigators according to Response Evalutaion Criteria in Solid Tumors (RECIST) v1.1 and immune-related RECIST (irRECIST)</measure>
    <time_frame>24 months</time_frame>
    <description>The time from date of randomization until the first occurrence of disease progression or death due to any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>24 months</time_frame>
    <description>Number of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), AE of special interest (AESI), serious adverse event (SAE), assessed by NCI CTCAE v5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>The time from date of randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP) assessed by investigators according to RECIST 1.1 and irRECIST</measure>
    <time_frame>24 months</time_frame>
    <description>The time from date of randomization until the first occurrence of disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) assessed by investigators according to RECIST 1.1 and irRECIST.</measure>
    <time_frame>24 months</time_frame>
    <description>The percentage of patients who had a best overall tumor response rating of complete response (CR) or partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) assessed by investigators according to RECIST 1.1 and irRECIST</measure>
    <time_frame>24 months</time_frame>
    <description>The percentage of patients who had a tumor response rating of CR, PR, or stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS assessed by investigators according to Modified RECIST (mRECIST)</measure>
    <time_frame>24 months</time_frame>
    <description>The time from date of randomization until the first occurrence of disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTP assessed by investigators according to mRECIST.</measure>
    <time_frame>24 months</time_frame>
    <description>The time from date of randomization until the first occurrence of disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR assessed by investigators according to mRECIST</measure>
    <time_frame>24 months</time_frame>
    <description>The percentage of patients who had a best overall tumor response rating of CR or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR assessed by investigators according to mRECIST.</measure>
    <time_frame>24 months</time_frame>
    <description>The percentage of patients who had a tumor response rating of CR, PR, or SD.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Hepatocellular Carcinoma Non-resectable</condition>
  <arm_group>
    <arm_group_label>Regorafenib + sintilimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regorafenib combined with sintilimab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regorafenib alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib + sintilimab</intervention_name>
    <description>Regorafenib: 160 mg p.o. qd for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off).&#xD;
Sintilimab: 200mg i.v. q3w.</description>
    <arm_group_label>Regorafenib + sintilimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>160 mg p.o. qd for 3 weeks of every 4 week cycle.</description>
    <arm_group_label>Regorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with unresectable HCC confirmed by histology/cytology or clinically.&#xD;
&#xD;
          -  Failure to prior sorafenib or lenvatinib treatment, or intolerance to sorafenib or&#xD;
             lenvatinib.&#xD;
&#xD;
          -  For patients who cannot tolerant to sorafenib or lenvatinib, the AEs must resolve to â‰¤&#xD;
             grade 1 (NCI-CTCAE v5.0) before randomization.&#xD;
&#xD;
          -  Child-Pugh class A.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment.&#xD;
&#xD;
          -  At least one measurable lesion.&#xD;
&#xD;
          -  Adequate organ and hematologic function.&#xD;
&#xD;
          -  Life expectancy of at least 3 months.&#xD;
&#xD;
          -  For women of childbearing potential and for men: agreement to remain abstinent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.&#xD;
&#xD;
          -  Diffuse HCC.&#xD;
&#xD;
          -  Portal vein tumor thrombus (PVTT) involves the main trunk and contralateral branch or&#xD;
             upper mesenteric vein.&#xD;
&#xD;
          -  Inferior vena cava tumor thrombus.&#xD;
&#xD;
          -  Metastatic disease that involves major airways or blood vessels.&#xD;
&#xD;
          -  Symptomatic, untreated or progressing central nervous system metastasis.&#xD;
&#xD;
          -  History of hepatic encephalopathy&#xD;
&#xD;
          -  History of organ and stem cell transplantation&#xD;
&#xD;
          -  Uncontrolled ascites, hydrothorax or pericardial effusion&#xD;
&#xD;
          -  Patients who receive systemic therapy except for sorafenib and lenvatinib within 4&#xD;
             weeks before randomization, including other molecular targeted drugs, chemotherapy&#xD;
             (including hepatic arterial infusion chemotherapy), immunotherapy, and herbal therapy&#xD;
             or traditional Chinese medicine with anti-cancer activity.&#xD;
&#xD;
          -  Prior esophageal and/or gastric varices bleeding within 6 months prior to initiation&#xD;
             of study treatment.&#xD;
&#xD;
          -  Untreated or incompletely treated esophageal and/or gastric varices with high-risk for&#xD;
             bleeding.&#xD;
&#xD;
          -  History of venous thromboembolism, but implantable i.v. ports, catheter-derived&#xD;
             thrombosis, superficial venous thrombosis, or thrombosis effectively treated by&#xD;
             regular anticoagulant therapy are excluded.&#xD;
&#xD;
          -  Use of anticoagulants which need monitoring of international normalized ratio.&#xD;
&#xD;
          -  Patients unable to swallow oral medications; Gastrointestinal malabsorption,&#xD;
             gastrointestinal anastomosis, or any other condition that may affect the absorption of&#xD;
             regorafenib.&#xD;
&#xD;
          -  Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture&#xD;
             underwent major surgery (craniotomy, thoracotomy or open surgery) within 4 weeks;&#xD;
             non-recovery from side effects of these procedure.&#xD;
&#xD;
          -  Active tuberculosis.&#xD;
&#xD;
          -  History of malignancy other than HCC within 5 years prior to screening. Patients with&#xD;
             skin basal cell carcinoma, skin squamous cell carcinoma, or carcinoma in situ (e.g.,&#xD;
             breast carcinoma and cervical carcinoma in situ) who have received potentially&#xD;
             curative treatment is allowed.&#xD;
&#xD;
          -  Hepatitis B is allowed if no active replication is present. Hepatitis C is allowed if&#xD;
             no antiviral treatment is required.&#xD;
&#xD;
          -  Co-infection of hepatitis B virus (HBV) and hepatitis C virus (HCV) or HBV and&#xD;
             hepatitis D virus (HDV).&#xD;
&#xD;
          -  Active infection requiring systemic treatment. Hepatitis B without active replication&#xD;
             is allowed. Hepatitis C not requiring antiviral treatment is allowed.&#xD;
&#xD;
          -  Use of antibiotics within 2 weeks prior to injection of sintilimab.&#xD;
&#xD;
          -  Use of immunosuppressive drugs in the past 4 weeks, excluding the routes of topical&#xD;
             glucocorticoids or physiological doses of systemic glucocorticoids (ie no more than 10&#xD;
             mg/day of prednisone or equivalent). Temporary use of glucocorticoids for dyspnea&#xD;
             symptoms such as asthma and chronic obstructive pulmonary disease is allowed.&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, interstitial pneumonia, drug-induced&#xD;
             pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis.&#xD;
&#xD;
          -  Autoimmune disease or immune deficiency.&#xD;
&#xD;
          -  Inadequately controlled hypertension; history of hypertensive crisis or hypertensive&#xD;
             encephalopathy.&#xD;
&#xD;
          -  Female patients who are pregnancy or breastfeeding.&#xD;
&#xD;
          -  Other acute or chronic diseases, mental illness, or abnormal laboratory test results&#xD;
             that may lead to the following outcomes: increase the risk of participating in study&#xD;
             or study drug administration, or interfere with the interpretation of the study&#xD;
             results and considered by investigator as &quot;NOT&quot; eligible to participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kangshun Zhu, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Second Affiliated Hospital of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jingjun Huang, Dr.</last_name>
    <phone>+86-20-34156205</phone>
    <email>junooi@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mingyue Cai, Dr.</last_name>
    <phone>+86-20-34156205</phone>
    <email>cai020@yeah.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>the Second Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510260</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingyue Cai, Dr.</last_name>
      <phone>+86-20-34156205</phone>
      <email>cai020@yeah.net</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Regorafenib</keyword>
  <keyword>Sintilimab</keyword>
  <keyword>Second-line treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

